Abbott Labs Finds Some Guidance - Guidant's stent business and a blockbuster drug will help Abbott's ailing stock

摘要

WALL STREET seems to have wearied of medical stocks. In the past five years, health care companies have fallen 5 percent as the S&P 500 stayed flat. But wherever there's bad news, there are value investors looking for bargains - and many are looking at Abbott Laboratories.